• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mavacamten for hypertrophic obstructive cardiomyopathy.

作者信息

Quintana Eduard, Bajona Pietro, Myers Patrick O

机构信息

Department of Cardiovascular Surgery, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.

Department of Cardiac Surgery, Allegheny Health Network, Drexel University College of Medicine, Pittsburgh, PA, USA.

出版信息

Lancet. 2021 Jan 30;397(10272):369. doi: 10.1016/S0140-6736(20)32384-9.

DOI:10.1016/S0140-6736(20)32384-9
PMID:33516331
Abstract
摘要

相似文献

1
Mavacamten for hypertrophic obstructive cardiomyopathy.
Lancet. 2021 Jan 30;397(10272):369. doi: 10.1016/S0140-6736(20)32384-9.
2
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病（EXPLORER-HCM）：一项随机、双盲、安慰剂对照、3 期临床试验的健康状况分析。
Lancet. 2021 Jun 26;397(10293):2467-2475. doi: 10.1016/S0140-6736(21)00763-7. Epub 2021 May 15.
3
Mavacamten for hypertrophic obstructive cardiomyopathy - Authors' reply.玛伐卡坦治疗肥厚性梗阻性心肌病——作者回复
Lancet. 2021 Jan 30;397(10272):369-370. doi: 10.1016/S0140-6736(20)32391-6.
4
Mavacamten (Camzyos) for obstructive hypertrophic cardiomyopathy.玛伐卡坦（卡姆佐）用于梗阻性肥厚型心肌病。
Med Lett Drugs Ther. 2022 Jun 13;64(1652):89-91.
5
Mavacamten: treatment aspirations in hypertrophic cardiomyopathy.玛伐卡坦：肥厚型心肌病的治疗期望
Lancet. 2020 Sep 12;396(10253):736-737. doi: 10.1016/S0140-6736(20)31793-1. Epub 2020 Aug 29.
6
Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial.接受间隔减容术的梗阻性肥厚型心肌病患者使用mavacamten治疗：VALOR-HCM试验中第56周的健康状况分析。
J Am Coll Cardiol. 2024 Sep 10;84(11):1041-1045. doi: 10.1016/j.jacc.2024.06.025.
7
Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.VALOR-HCM 研究的设计和原理：评估马卡塞特在有症状的梗阻性肥厚型心肌病成人患者中的疗效，这些患者有资格接受间隔减少治疗。
Am Heart J. 2021 Sep;239:80-89. doi: 10.1016/j.ahj.2021.05.007. Epub 2021 May 24.
8
Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.EXPLORER-HCM 研究的设计和原理：评价马卡坦特治疗有症状梗阻性肥厚型心肌病成人患者的疗效。
Circ Heart Fail. 2020 Jun;13(6):e006853. doi: 10.1161/CIRCHEARTFAILURE.120.006853. Epub 2020 Jun 5.
9
Exploring New and Old Therapies for Obstructive Hypertrophic Cardiomyopathy: Mavacamten in Perspective.探索梗阻性肥厚型心肌病的新旧疗法：马伐卡坦的前景
Circulation. 2021 Mar 23;143(12):1181-1183. doi: 10.1161/CIRCULATIONAHA.120.051330. Epub 2021 Mar 22.
10
[EXPLORER-HCM: mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy].[探索者-HCM：mavacamten用于治疗有症状的梗阻性肥厚型心肌病]
G Ital Cardiol (Rome). 2021 Jan;22(1):30-32. doi: 10.1714/3502.34878.

引用本文的文献

1
Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials.心肌肌球蛋白抑制剂mavacamten和aficamten在肥厚型心肌病中的疗效：一项随机对照试验的系统评价和荟萃分析
Open Heart. 2025 Feb 23;12(1):e003215. doi: 10.1136/openhrt-2025-003215.
2
Differentiating Cardiac Troponin Levels During Cardiac Myosin Inhibition or Cardiac Myosin Activation Treatments: Drug Effect or the Canary in the Coal Mine?在心肌肌球蛋白抑制或心肌肌球蛋白激活治疗期间区分肌钙蛋白水平：是药物作用还是煤矿中的金丝雀？
Curr Heart Fail Rep. 2023 Dec;20(6):504-518. doi: 10.1007/s11897-023-00620-2. Epub 2023 Oct 25.
3
Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy.
梗阻性肥厚型心肌病患者使用丙吡胺的真实世界应用及反应预测因素
J Clin Med. 2023 Apr 6;12(7):2725. doi: 10.3390/jcm12072725.
4
Future Role of New Negative Inotropic Agents in the Era of Established Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.新型负性肌力药物在症状性梗阻性肥厚型心肌病既定手术心肌切除术时代的未来作用。
J Am Heart Assoc. 2022 May 3;11(9):e024566. doi: 10.1161/JAHA.121.024566.
5
The consolidation of surgery for hypertrophic obstructive cardiomyopathy in Asia and the Pacific Rim.亚太地区肥厚型梗阻性心肌病外科治疗的整合
Asian Cardiovasc Thorac Ann. 2022 Jan;30(1):5-7. doi: 10.1177/02184923211057323. Epub 2021 Nov 6.